Skip to main content

Advertisement

Table 3 Hepatorenal and blood cell characteristics of Study 2 participants

From: Acute and chronic safety and efficacy of dose dependent creatine nitrate supplementation and exercise performance

   Day   
Marker Group 0 7 28   p-level
Hepatorenal      
 ALPS PLA 11.2 ± 14.6 10.5 ± 10.7 12.4 ± 10.9 Group 0.44
 (U/L) CrM 11.4 ± 9.5 12.0 ± 10.4 11.0 ± 7.8 Time 0.36
  CrN-Low 15.5 ± 11.4 16.2 ± 11.9 19.5 ± 15.9 Group × Time 0.85
  CrN-High 12.0 ± 7.1 13.6 ± 6.1 14.3 ± 11.7   
 ALT PLA 27.2 ± 8.6 30.2 ± 13.8 32.1 ± 30.6 Group 0.24
 (U/L) CrM 28.9 ± 16.6 25.1 ± 10.0 32.7 ± 22.9 Time 0.06
  CrN-Low 21.3 ± 6.7 19.9 ± 4.4 22.4 ± 6.7 Group × Time 0.70
  CrN-High 28.7 ± 13.2 30.0 ± 15.7 36.8 ± 23.2   
 AST PLA 31.2 ± 13.3 30.1 ± 11.6 29.5 ± 13.4 Group 0.90
 (U/L) CrM 28.3 ± 10.2 26.4 ± 7.7 32.5 ± 12.3 Time 0.56
  CrN-Low 26.0 ± 7.0 30.6 ± 25.3 26.0 ± 6.0 Group × Time 0.47
  CrN-High 26.4 ± 5.9 28.7 ± 7.0 32.0 ± 7.6   
 CK PLA 252 ± 128 294 ± 399 206 ± 161 Group 0.79
 (U/L) CrM 285 ± 169 345 ± 319 409 ± 373 Time 0.35
  CrN-Low 283 ± 169 480 ± 987 243 ± 136 Group × Time 0.56
  CrN-High 284 ± 171 349 ± 203 424 ± 287   
 LDH PLA 226 ± 180 167 ± 29 158 ± 34 Group 0.93
 (U/L) CrM 185 ± 62 172 ± 39 184 ± 48 Time 0.20
  CrN-Low 175 ± 50 173 ± 41 166 ± 29 Group × Time 0.23
  CrN-High 173 ± 29 176 ± 30 182 ± 39   
 BUN PLA 16.3 ± 3.6 15.6 ± 5.2 15.7 ± 4.9 Group 0.64
 (mg/dl) CrM 15.3 ± 5.5 15.2 ± 4.9 16.3 ± 6.1 Time 0.48
  CrN-Low 14.9 ± 3.8 13.3 ± 3.9 13.5 ± 4.6 Group × Time 0.64
  CrN-High 14.6 ± 3.2 14.8 ± 2.7 15.7 ± 5.8   
 Creatinine PLA 1.18 ± 0.26 1.19 ± 0.33 1.15 ± 0.27 Group 0.97
 (mg/dl) CrM 1.15 ± 0.46 1.26 ± 0.36 1.23 ± 0.39 Time 0.001
  CrN-Low 1.09 ± 0.25 1.21 ± 0.31 1.23 ± 0.31 Group × Time 0.12
  CrN-High 1.12 ± 0.18 1.15 ± 0.23 1.20 ± 0.23   
 BUN: Creatinine PLA 14.2 ± 3.7 13.9 ± 6.8 13.6 ± 3.1 Group 0.78
 (mg/dl) CrM 13.7 ± 3.6 12.8 ± 5.3 14.0 ± 6.1 Time 0.07
  CrN-Low 14.1 ± 4.2 11.4 ± 3.8 11.3 ± 3.4 Group × Time 0.13
  CrN-High 13.3 ± 3.8 13.3 ± 3.3 13.4 ± 4.8   
Blood cell characteristics     
 MCV PLA 92.2 ± 3.1 91.7 ± 3.7 91.6 ± 3.8 Group 0.79
 (fL) CrM 93.0 ± 3.9 93.7 ± 3.9 93.6 ± 4.7 Time 0.47
  CrN-Low 91.7 ± 3.8 91.8 ± 4.0 92.3 ± 4.2 Group × Time 0.49
  CrN-High 93.3 ± 3.0 93.4 ± 3.1 88.7 ± 17.7   
 MCH PLA 30.4 ± 1.7 30.5 ± 1.3 31.0 ± 2.3 Group 0.45
 (pg/cell) CrM 30.6 ± 1.4 31.2 ± 1.5 31.0 ± 2.6 Time 0.23
  CrN-Low 30.6 ± 1.7 31.6 ± 2.1 31.3 ± 2.2 Group × Time 0.92
  CrN-High 31.2 ± 0.9 31.3 ± 1.4 31.5 ± 1.2   
 MCHC PLA 32.9 ± 1.2 33.3 ± 1.7 33.8 ± 1.8 Group 0.40
 (g/dl) CrM 32.9 ± 0.7 33.3 ± 1.5 33.1 ± 1.9 Time 0.53
  CrN-Low 33.3 ± 0.8 34.5 ± 3.4 33.9 ± 1.7 Group × Time 0.66
  CrN-High 33.5 ± 0.7 33.5 ± 1.6 32.2 ± 6.0   
 RBCDW PLA 13.2 ± 0.5 13.1 ± 0.9 13.1 ± 0.3 Group 0.02
 (%) CrM 13.5 ± 0.9 13.7 ± 0.9 13.9 ± 0.8 Time 0.11
  CrN-Low 13.6 ± 0.6 13.4 ± 0.6 13.5 ± 0.7 Group × Time 0.66
  CrN-High 12.8 ± 0.6 13.2 ± 0.6 13.1 ± 0.4   
 Platelet Count PLA 206 ± 36 188 ± 32 208 ± 70 Group 0.35
 (x103/μL) CrM 234 ± 57 226 ± 91 255 ± 51 Time 0.56
  CrN-Low 218 ± 69 183 ± 50 194 ± 68 Group × Time 0.39
  CrN-High 220 ± 61 412 ± 713 224 ± 59   
 WBC PLA 6.2 ± 1.7 5.3 ± 1.5 6.2 ± 1.1 Group 0.72
 (x103/μL) CrM 6.0 ± 1.7 6.6 ± 1.3 6.4 ± 1.3 Time 0.58
  CrN-Low 6.2 ± 1.6 5.9 ± 1.8 5.4 ± 1.3 Group × Time 0.18
  CrN-High 5.9 ± 1.4 5.5 ± 1.6 6.1 ± 1.6   
 RBC PLA 5.2 ± 0.8 5.01 ± 0.83 4.8 ± 0.6 Group 0.25
 (x106/μL) CrM 5.3 ± 0.6 5.60 ± 0.97 5.1 ± 0.8 Time 0.09
  CrN-Low 5.0 ± 0.5 5.11 ± 0.95 4.9 ± 0.7 Group × Time 0.65
  CrN-High 5.5 ± 0.8 5.08 ± 0.51 5.1 ± 0.5   
 Hematocrit PLA 47.7 ± 7.1 46.0 ± 8.2 44.0 ± 4.5 Group 0.16
 (%) CrM 49.5 ± 6.7 52.5 ± 9.7 47.6 ± 8.4 Time 0.51
  CrN-Low 46.2 ± 5.5 47.1 ± 10.3 44.8 ± 7.1 Group × Time 0.44
  CrN-High 51.2 ± 7.8 47.5 ± 5.2 51.7 ± 15.4   
 Hemoglobin PLA 15.7 ± 2.5 15.3 ± 2.7 14.8 ± 1.2 Group 0.17
 (g/dl) CrM 16.3 ± 2.1 20.1 ± 10.2 15.7 ± 2.8 Time 0.63
  CrN-Low 15.4 ± 2.1 16.1 ± 3.1 15.2 ± 2.3 Group × Time 0.19
  CrN-High 17.2 ± 2.7 15.9 ± 1.4 18.7 ± 9.5   
  1. Data are mean ± SD